9 Things to Know About Apigenin Before Using It for Menopause Sleep and Neuroinflammation
When sleep started fracturing every night around 3am, the rabbit hole that followed led straight to apigenin — it seemed to be everywhere online, spoken about in the same breath as NMN and NAD+ like some kind of gentle miracle. What was harder to find was anyone explaining the GABA connection clearly, or mentioning that chamomile has been sedating people for centuries for exactly this reason. Knowing the mechanism doesn't make the sleepless nights easier, but it does make the decision about whether to try something feel a lot less like guesswork.
Learn more about Rose →Apigenin is a GABA-A receptor modulator — and that's why it makes people sleepy
Apigenin binds to benzodiazepine-sensitive sites on GABA-A receptors in the brain, producing a mild anxiolytic and sedative effect by enhancing the inhibitory action of GABA, the brain's primary calming neurotransmitter. This is the same receptor class targeted by benzodiazepines and Z-drugs, though apigenin's binding affinity is considerably weaker and its effect profile is far gentler. For perimenopausal women whose sleep disruption is driven partly by heightened nervous system arousal and declining progesterone — which itself was a natural GABA-A modulator — this mechanism is genuinely relevant rather than speculative.
Progesterone decline in perimenopause directly affects the same receptor pathway
Progesterone is metabolised into allopregnanolone, a potent positive allosteric modulator of GABA-A receptors that promotes calm and deep sleep — and its levels drop significantly during perimenopause. As allopregnanolone falls, many women experience increased anxiety, lighter sleep architecture, and more frequent night waking, all of which reflect reduced GABAergic tone. Apigenin's appeal in this context makes physiological sense: it's not a replacement for progesterone, but it acts on the same downstream receptor system through a different entry point.
It's a CD38 inhibitor, which is why it appears in NAD+ longevity stacks
CD38 is an enzyme that consumes NAD+ — a coenzyme critical for cellular energy production and DNA repair — and its activity increases significantly with age and chronic inflammation. Apigenin inhibits CD38, which in theory helps preserve intracellular NAD+ levels, and this is why it frequently appears alongside NMN or NR in supplement formulations aimed at supporting mitochondrial function and reducing biological aging. For perimenopausal women, falling oestrogen accelerates mitochondrial dysfunction and inflammatory signalling, giving the NAD+-preservation angle some indirect relevance, though direct clinical trials in this population are lacking.
Its anti-neuroinflammatory effects are real but mostly demonstrated in animal models
Apigenin has shown consistent anti-inflammatory activity in preclinical research, including inhibition of NF-κB signalling, reduction of pro-inflammatory cytokines like IL-6 and TNF-α, and suppression of microglial activation — the brain's resident immune cells that drive neuroinflammation. Neuroinflammation is increasingly recognised as a contributor to menopause-related cognitive symptoms including brain fog, word-finding difficulties, and mood instability. The animal evidence is mechanistically convincing, but human trials specifically examining neuroinflammatory outcomes in midlife women are not yet available, so this remains a biologically plausible rather than clinically proven benefit.
Chamomile tea contains apigenin but at doses far below most supplement capsules
A standard cup of chamomile tea delivers roughly 0.5–1mg of apigenin depending on steeping time and variety, whereas supplement capsules typically contain 50mg to 100mg per dose — a 50 to 100-fold difference. This matters because the mild sedative effects of chamomile tea have been used safely across cultures for centuries, but the long-term safety profile of concentrated supplemental doses is not established with the same confidence. Women who have found chamomile tea helpful for sleep are essentially already using low-dose apigenin, which is a useful reference point when thinking about whether to escalate to a capsule form.
Apigenin has oestrogenic activity at the cellular level — a detail frequently overlooked
Apigenin is classified as a phytoestrogen, meaning it can bind to oestrogen receptors (particularly ERβ) and exert weak oestrogenic effects in some tissues. For most healthy perimenopausal women this is unlikely to be clinically significant at typical supplement doses, but it is relevant for anyone with a history of hormone-sensitive cancers, endometriosis, or conditions where oestrogen modulation carries risk. This oestrogenic activity should be part of any conversation with a GP or oncologist before use, and it is notably absent from most supplement marketing around apigenin.
The human sleep evidence is limited but directionally positive
Small randomised trials using chamomile extract (standardised for apigenin) have shown modest improvements in sleep quality measures in postmenopausal women and older adults, including reduced time to sleep onset and improved subjective sleep quality. A 2017 RCT published in the journal Phytomedicine found significant improvements in sleep quality in elderly adults given chamomile extract compared to placebo over 28 days. These trials are encouraging but small, short in duration, and use extract rather than isolated apigenin, making direct dose extrapolation to standalone apigenin supplements imprecise.
Drug interactions are a legitimate concern, particularly with sedatives and blood thinners
Because apigenin acts on GABA-A receptors, combining it with benzodiazepines, Z-drugs (like zopiclone), alcohol, or other sedating substances could produce additive CNS depression — meaning greater sedation than intended. Apigenin also inhibits certain cytochrome P450 liver enzymes (particularly CYP1A2 and CYP3A4), which are responsible for metabolising a wide range of medications including some antidepressants, anticoagulants like warfarin, and thyroid medications. Women taking any regular prescription medication should check for potential interactions before starting apigenin supplementation.
Timing and dose matter more than most supplement guides acknowledge
Given its GABA-A activity and sedative potential, most practitioners familiar with apigenin recommend taking it in the evening rather than during the day, where it could impair alertness or concentration — a real concern for women already managing menopause-related cognitive symptoms. Doses used in research range from 25mg to 100mg, and anecdotal reports suggest that some women find even 25mg sufficient for sleep support while others notice little effect at 50mg, reflecting individual variation in absorption and receptor sensitivity. Starting low and observing response over one to two weeks before adjusting is the most sensible approach, and cycling off periodically is a reasonable precaution given the lack of long-term human safety data.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.